Tag: Novartis
Parents Who Have Lost a Child to Anaphylaxis Speak Out in...
BSACI and ITN have released a program entitled "Allergy and Clinical Immunology – Attention Needed!" to raise awareness and educate.
Symjepi, the Once Promising Emergency Epinephrine Device, Continues to Stumble
It's back to square one.
Clinical Trial to Evaluate Experimental Treatment in People Allergic to Multiple...
NIH and partners to assess whether Omalizumab can reduce allergic reactions.
FDA Confirms Adrenaclick® Generic and EpiPen® Still in Short Supply with...
Shortages of auto-injectors continue. Consider these alternatives.
Protecting Against Severe Allergic Reactions This Summer
Life-saving medication on the way to U.S. clinics serving low-income and uninsured patients.
Symjepi, the Auto-Injector Alternative, to Launch Q1 2019
Prefilled syringe will join auto-injectors for emergency delivery of epinephrine.
FDA Grants Xolair Breakthrough Therapy Designation for Food Allergies
Breakthrough Therapy Designation was granted on the basis of data from seven clinical studies assessing the efficacy and safety of Xolair against a range of food allergens including peanut, milk, egg and others.
Symjepi Back on Track After Adamis Finds Commercialization Partner
Partnership paves way for introduction of device already approved by the FDA.
